Gain Therapeutics’ supercomputer-driven therapy offers potential Parkinson’s breakthrough

The AI-powered drug discovery platform Magellan paved the way for GT-02287, a potential disease-modifying treatment for Parkinson’s disease. [Image: Gain Therapeutics]

The Bethesda biotech Gain Therapeutics, armed with supercomputer firepower, aims to disrupt Parkinson’s disease treatment. Their GCase regulator, named GT-02287, completely restored motor function in a recent animal study.

GCase, short for glucocerebrosidase, targets both lysosomal and mitochondrial dysfunction. In Parkinson’s, the failure of cellular powerhouses (mitochondria) and recycling centers (lysosomes) disrupts essential functions. This breakdown leads to a toxic buildup of glycosphingolipids (fatty substances within cells) and damaging clumps of alpha-synuclein (a misfolded protein), hallmarks of Parkinson’s disease and the cause of Lewy bodies. For a visual explanation of this process, see the diagram several par…

Read more
  • 0

CLN-619 antibody therapy offers a new hope for patients with advanced solid tumors

Illustration of Fragment Crystallizable (Fc)-mediated cytotoxicity boosting tumor cell destruction. It highlights the increased MICA-NKG2D interaction, enhancing NK cell/T cell activation, and shows the reduction of MICA/MICB decoy release, improving NKG2D functionality. [Image courtesy of Cullinan Oncology]

Boston-based Cullinan Oncology has unveiled data for its new monoclonal antibody therapy, CLN-619, ahead of the American Society of Clinical Oncology (ASCO) 2023 meeting scheduled for June 2–6 in Chicago. The drug could potentially offer a new treatment option for patients with advanced solid tumors.

Dr. Judy Wang, Associate Director of Drug Development at the Florida Cancer Specialists and Research Institute, explained the science behind the therapy. “CLN-619 is a human IgG1 monoclonal antibody that binds to cell surface ligands called MICA and MICB. These new immune therapies are trying to overcome t…

Read more
  • 0